About Joshua Kazam
Joshua Kazam is a director at Allogene Therapeutics.
Form D filings name Joshua Kazam as a director and promoter at IconOVir Bio.
Joshua Kazam reports to the SEC as a director or officer of 13 public companies, including Kronos Bio (KRON), Screaming Eagle Acquisition (SCRM) and Latch (LTCH).
Joshua Kazam first appears on SEC filings in 2007.
Experience
This experience comes from SEC filings. The years are when the filings name Joshua Kazam in the role, so the role may have started earlier or lasted longer.
AI
Allogene Therapeutics, Inc.
Director
2018 – 2026 · Public company (ALLO)
KI
Kronos Bio, Inc.
Director
2020 – 2025 · Public company (KRON)
SC
Screaming Eagle Acquisition Corp.
Director
2022 · Public company (SCRM)
LI
Latch, Inc.
Director
2020 – 2021 · Public company (LTCH)
GI
Ginkgo Bioworks Holdings, Inc.
Director
2021 · Public company (DNA)
TI
Tishman Speyer Innovation Corp. II
Director
2021 · Public company (TSIB)
FI
Firy Inc.
Director
2020 · Public company (FIRY)
DI
DraftKings Holdings Inc.
Director
2019 · Public company (DKNG)
TC
Target Hospitality Corp.
Director
2018 – 2019 · Public company (TH)
CI
Capricor Therapeutics, Inc.
President & CEO, director
2007 – 2018 · Public company (CAPR)
KI
Kite Pharma, Inc.
Director
2014 – 2017 · Public company (KITE)
AI
Arno Therapeutics, Inc
Director
2008 · Public company (ARNI)
VI
Velcera, Inc.
Director
2007 – 2008 · Public company (VLCR)
Key Colleagues at Startups
The people Joshua Kazam works with at each company, as listed on that company's latest Form D.
IconOVir Bio, Inc. · Form D/A, Jun 4, 2024
SA
Sean Algeo
Executive officer and promoter
NL
Nicole van de Leuv
Executive officer
HK
Helen Kim
Director
HN
Heba Nowyhed
Executive officer
DC
David Chang
Director and promoter
WK
William Kaelin
Director
JL
Jakob Loven
Director
JM
Julie Maltzman
Executive officer
MM
Mark McCamish
Executive officer and director
JH
John Huynh
Executive officer
DT
David Tanen
Secretary